Penicillamine and the SLE syndrome.
Penicillamine-induced systemic lupus erythematosus (SLE) and penicillamine-immune complex nephritis are histologically and serologically distinct. One hundred and twenty patients with Wilson's disease treated with penicillamine have been analyzed. Eight developed the serologic changes of SLE; in 4, it was necessary to discontinue treatment. In addition, 6 patients developed immune complex nephritis, which necessitated discontinuing treatment. All but 1 have since been managed on triethylene tetramine 2HCl (Trien).
D000293:Adolescent; D000328:Adult; D002614:Chelating Agents / Q000627:therapeutic use; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D008297:Male; D008345:Manganese / Q000097:blood / Q000378:metabolism; D010396:Penicillamine / Q000009:adverse effects*
D002614:Chelating Agents; D008345:Manganese; D010396:Penicillamine